Literature DB >> 11748783

Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions.

B Lawlor1, S N Bhriain.   

Abstract

Neuroleptics have a definite role in dementia but the treatment targets need to be more narrowly defined. Symptom clusters that are neuroleptic-responsive (e.g., aggression, psychomotor agitation and psychosis) appear to be emerging but need clearer definition and measurement. A number of these symptom clusters are relatively persistent over time and associated with increased risk of institutionalization, underscoring the need for treatment. The frequency, severity and persistence of the symptom or behaviour, the context in which it occurs and its impact on the carer must be considered before prescribing a neuroleptic. Given the modest effect size for neuroleptic interventions, the safety and tolerability of the agent is also a key factor in determining drug choice. Novel neuroleptics are safer and better tolerated and therefore should be used in preference to conventional agents when neuroleptic treatment is indicated for behavioural and psychological symptoms of dementia. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748783     DOI: 10.1002/1099-1166(200112)16:1+<::aid-gps567>3.0.co;2-p

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  11 in total

1.  Psychotic symptoms in the elderly.

Authors:  Rebecca W Brendel; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 2.  Risperidone for the treatment of neuropsychiatric features in dementia.

Authors:  Alistair Burns; Peter P De Deyn
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Authors:  Dong-Churl Suh; Stephen Arcona; Simu K Thomas; Christopher Powers; Adrian L Rabinowicz; Hyunchul Shin; Dario Mirski
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Giuseppe Cazzato; Antonio Bava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Prevalence and treatment of neuropsychiatric symptoms in advanced dementia.

Authors:  Karan S Kverno; Peter V Rabins; David M Blass; Kathryn L Hicks; Betty S Black
Journal:  J Gerontol Nurs       Date:  2008-12       Impact factor: 1.254

6.  Neuropsychiatric symptom patterns in hospice-eligible nursing home residents with advanced dementia.

Authors:  Karan S Kverno; Betty S Black; David M Blass; Jeanne Geiger-Brown; Peter V Rabins
Journal:  J Am Med Dir Assoc       Date:  2008-07-30       Impact factor: 4.669

7.  The effect of comorbidity burden on health care utilization for patients with cancer using hospice.

Authors:  Aron Legler; Elizabeth H Bradley; Melissa D A Carlson
Journal:  J Palliat Med       Date:  2011-05-06       Impact factor: 2.947

8.  Agitated behaviors among elderly people with dementia living in their home in Taiwan.

Authors:  Huei-Ling Huang; Yea-Ing L Shyu; Wen-Chuin Hsu
Journal:  Clin Interv Aging       Date:  2018-06-29       Impact factor: 4.458

9.  Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Susanna Pietropaolo; Joram Feldon; Benjamin K Yee
Journal:  Cogn Affect Behav Neurosci       Date:  2014-09       Impact factor: 3.526

10.  Self-management by family caregivers to manage changes in the behavior and mood of their relative with dementia: an online focus group study.

Authors:  Judith Huis In Het Veld; Renate Verkaik; Berno van Meijel; Paul-Jeroen Verkade; Wendy Werkman; Cees Hertogh; Anneke Francke
Journal:  BMC Geriatr       Date:  2016-05-03       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.